19th Dec 2012 10:50
Sinclair IS Pharma and Biocodex Sign 10-year Partnership to Commercialise Portfolio in Emerging Markets and Benelux
LONDON and PARIS - December 19, 2012 - Biocodex and Sinclair IS Pharma plc ("Sinclair") announce the signing of a 10-year collaboration and licensing agreement for Biocodex to commercialise Sinclair's dermatology portfolio in Russia, Turkey, and the Benelux countries.
Under the agreement, Biocodex will be responsible for handling product importation, distribution to wholesalers, salesforce promotion to clinicians and pharmacies, and marketing, advertising, and promotion.
"This partnership with Biocodex supports our growth strategy to create relationships with strong strategic partners and move our product portfolio into fast-growing, emerging markets" said Chris Spooner, Chief Executive Officer, Sinclair. "We already have a successful distribution partnership with Biocodex in Turkey, which provides the foundation for this new multi-product, multi-country arrangement."
The agreement with Biocodex includes the following products: Kelo-cote® silicone-gel scar reduction range for the prevention and management of abnormal scars; Sculptra® collagen stimulator for gradual and natural deep tissue regeneration; Papulex® for the management and maintenance of mild to moderate acne; Bio-Taches® for hyperpigmentation disorders; Atopiclair® for the treatment of mild to moderate atopic dermatitis; and Sebclair® for the treatment of seborrhoeic dermatitis.
Ends
For further information please contact:
Sinclair IS Pharma plc Tel: +44 (0) 20 7467 6920
Chris Spooner
Alan Olby
Robert Taylor
Peel Hunt LLP Tel: +44 (0) 20 7418 8900
James Steel
Vijay Barathan
Notes to Editors:
About Sinclair IS Pharma plc - www.sinclairispharma.com
Sinclair IS Pharma is an international specialty pharmaceutical company focused on treatments in dermatology, wound care, oncology support and critical care through advanced surface technology and innovative delivery systems. The Company has a growing sales and marketing operation with a direct sales presence in the top five European markets and an extensive marketing partner network across selected developed and emerging markets.
Related Shares:
Sinclair Pharma